
|Videos|December 26, 2016
Access to PCSK9 Inhibitors Remains a Challenge
Author(s)Lauren Santye, Assistant Editor
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses challenges in gaining access to cholesterol-lowering PCSK9 inhibitors.
Advertisement
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses challenges in gaining access to cholesterol-lowering PCSK9 inhibitors.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Integrating Combination Therapies for Type 2 Diabetes and CKD
2
Sotatercept Demonstrates Significant Reduction in Morbidity and Mortality Across Broader PAH Risk Groups
3
Building a Unified Approach to Cardio Kidney Metabolic Health
4
SGLT2 Inhibitors Linked to Lower Atrial Fibrillation Risk, Recurrence
5












































































































































































































